Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
5 Stocks With Recent Price Strength Amid Wall Street Turmoil
08:28am, Tuesday, 01'st Feb 2022
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are DAC, ESTE, HAFC, ADM and VRTX.
3 Biotech Stocks That Could Boom or Bust in Q1
06:00am, Tuesday, 01'st Feb 2022
The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future.
Why Vertex Is One Of The Best Biotech Stocks To Own
05:57am, Monday, 31'st Jan 2022
Why Vertex Is One Of The Best Biotech Stocks To Own
Vertex Pharmaceuticals: DCF Modeling Of Legacy CFTR Portfolio Supports A Long Position
02:37pm, Sunday, 30'th Jan 2022
CFTR modulators portfolio of Vertex Pharmaceuticals supports a value of $297 per share. Relative to this, the share price of $228.22 (as of Jan 27, 2022) represents an undervaluation of at least 30%.
Market Dip? Here's Why This Bargain Biotech Is a Smart Buy Now
06:00am, Friday, 28'th Jan 2022
This company is a market leader -- and business is growing.
The Smartest Stocks to Buy With $500 in 2022
05:36am, Friday, 28'th Jan 2022
A relatively small amount of money can go a long way when invested in high-quality companies.
Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice
01:50pm, Thursday, 27'th Jan 2022
Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Vertex's Q4 2021 Earnings: More Of The Usual
10:48am, Thursday, 27'th Jan 2022
Vertex beat Q4 2021 earnings and revenue estimates and guided for 2022 revenue above the Street consensus. The results are not surprising given the company's beat-and-raise history.
Vertex Pharmaceuticals (VRTX) Q4 2021 Earnings Call Transcript
07:30am, Thursday, 27'th Jan 2022 The Motley Fool
VRTX earnings call for the period ending December 31, 2021.
Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q4 2021 Results - Earnings Call Transcript
02:31am, Thursday, 27'th Jan 2022 Seeking AlphaVertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q4 2021 Results - Earnings Call Transcript
09:31pm, Wednesday, 26'th Jan 2022
Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q4 2021 Results - Earnings Call Transcript
Vertex Pharmaceuticals Non-GAAP EPS of $3.37 beats by $0.08, revenue of $2.07B beats by $60M
09:02pm, Wednesday, 26'th Jan 2022 Seeking Alpha
Vertex Pharmaceuticals press release (NASDAQ:VRTX): Q4 Non-GAAP EPS of $3.37 beats by $0.08.Revenue of $2.07B (+27.0% Y/Y) beats by $60M.
Vertex Pharmaceuticals (VRTX) Surpasses Q4 Earnings and Revenue Estimates
06:25pm, Wednesday, 26'th Jan 2022
Vertex (VRTX) delivered earnings and revenue surprises of 2.74% and 4.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Buy-Ranked Stocks Likely to Beat on Earnings This Week
01:08pm, Tuesday, 25'th Jan 2022
The Zacks Rank and ESP are still a solid combination to predict earnings beats.
Vertex Investors Look Out...AbbVie Data In Cystic Fibrosis Coming Soon
12:56pm, Tuesday, 25'th Jan 2022
AbbVie will be releasing Phase 2 data for its experimental Cystic Fibrosis (CF) drugs that could potentially compete with Vertex's drugs. VRTX stock may move up or down, inversely related to the AbbVi
